TRPV1 agonist for Increasing Systemic Blood Pressure in Septic Shock

Contracts Guide

Disclose Your Invention
MTA/CDA Assistance
COVID-19 Related Agreements
Main Campus Research
Office of Sponsored Research
Education Links

Connect with Industry

Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials

Categories: “Cardiovascular Diseases”  “Other Disorders

Reference #: 2019-035

OTC Contact: : Ruchika Nijhara, PhD, MBA, CLP Office: (202) 687-3721 (Directory Information | Send a Message)


Angiotensin II ( GIAPREZA TM)) infusion, the newest treatment for blood pressure control during septic shock has certain limitations.  The present invention overcomes such limitations. The invention is directed to using TRPV1 agonist for increasing blood pressure in septic shock.


TRPV1 agonist can be used to stabilize blood pressure in severe sepsis/septic shock and other types of distributive shock


TRPV1 is not expressed in arterial blood supply of the spleen/kidney/liver so TRVP1-mediated vasoconstriction can safely maintain blood pressure while preserving blood flow to these critical organs. This is one of the major advantages over the standard treatments, such as adrenergic and dopamine agonists which compromise blood flow to vital organs, eg. Giapreza impairs flow to kidney, spleen and has pro-coagulant properties that can exacerbate coagulation.


Severe sepsis is a leading cause of death in the United States, affecting 300 out of 100,000 in the nation. it is the most common cause of death among critically ill patients in non-coronary intensive care units (ICU). The mortality outlook for such patients ranges from 25-50%, underscoring the need for effective treatment. Severe sepsis is associated with hyper-inflammation hypotension and edema. Standard treatment for hypotensive shock includes vasoconstrictor drugs (adrenergic/dopamine agonists). However, these drugs lose their effectiveness as these compromise blood flow to vital organs such as spleen and kidney. Further Giapreza has relatively modest efficacy and thus there is clearly a needed for better treatment options for severe sepsis.


TRPV1 specifically localizes to small arterioles in numerous tissues. Further, the data shows that TRPV1 controls rapid myogenic tone and systemic blood pressure and provide a novel method in the treatment of circulatory collapse that is critical in the control and reversal of septic shock.


Patent application filed.


Gerard Ahern
Thieu Phan